Introduction: Up to 30% of CML patients will require a therapeutic change during follow-up due to intolerance and/or resistance to first-line tyrosine kinase inhibitor (TKI) approach. In this context, bosutinib (BOS) has not only demonstrated its efficacy, but also presents a favorable safety profile, without comorbid conditions representing an absolute contraindication to its use. Methods: To gain further into BOS treatment in real life, we conducted a retrospective analysis on the outcome of CML patients receiving BOS in 18 hematological centers, all belonging to the “REL” (Lombard Hematology Network). Results: Of 546 regularly followed CML cases, a total of 132 patients were reported as being treated with BOS, most frequently (62.9%) in second line. Interestingly, most patients (63.6%) switched to BOS due to intolerance to the previous TKI, while resistance to the last treatment was reported in the remaining 36.4% of patients. Despite a permanent discontinuation rate of 18.9%, over 80% of patients achieved at least a major molecular response and seven cases were able to attempt treatment-free remission. Conclusion: Although in this survey BOS represented the preferred option especially in patients intolerant rather than resistant to previous TKIs, we confirmed that BOS represents a safe and effective therapeutic option beyond the first line in the real-life setting.

1.
Bower
H
,
Björkholm
M
,
Dickman
PW
,
Höglund
M
,
Lambert
PC
,
Andersson
TM
.
Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population
.
J Clin Oncol
.
2016
;
34
(
24
):
2851
7
.
2.
Hehlmann
R
,
Lauseker
M
,
Saussele
S
,
Pfirrmann
M
,
Krause
S
,
Kolb
HJ
, et al
.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
.
Leukemia
.
2017
;
31
(
11
):
2398
406
.
3.
Kantarjian
HM
,
Jabbour
EJ
,
Lipton
JH
,
Castagnetti
F
,
Brümmendorf
TH
.
A review of the therapeutic role of bosutinib in chronic myeloid leukemia
.
Clin Lymphoma Myeloma Leuk
.
2024
;
24
(
5
):
285
97
.
4.
Kong
JH
,
Khoury
HJ
,
Kim
AS
,
Hill
BG
,
Kota
V
.
The safety of Bosutinib for the treatment of chronic myeloid leukemia
.
Expert Opin Drug Saf
.
2017
;
16
(
10
):
1203
9
.
5.
Cortes
JE
,
Apperley
JF
,
DeAngelo
DJ
,
Deininger
MW
,
Kota
VK
,
Rousselot
P
, et al
.
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
.
J Hematol Oncol
.
2018
;
11
(
1
):
143
.
6.
Khoury
HJ
,
Gambacorti-Passerini
C
,
Brümmendorf
TH
.
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
.
Ann Oncol
.
2018
;
29
(
3
):
578
87
.
7.
Tiribelli
M
,
Abruzzese
E
,
Capodanno
I
,
Sorà
F
,
Trabacchi
E
,
Iurlo
A
, et al
.
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy
.
Ann Hematol
.
2019
;
98
:
2609
11
.
8.
Gambacorti-Passerini
C
,
Cortes
JE
,
Lipton
JH
,
Kantarjian
HM
,
Kim
DW
,
Schafhausen
P
, et al
.
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
.
Haematologica
.
2018
;
103
(
8
):
1298
307
.
9.
Castagnetti
F
,
Bocchia
M
,
Abruzzese
E
,
Capodanno
I
,
Bonifacio
M
,
Rege-Cambrin
G
, et al
.
Bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the BEST study
.
HemaSphere
.
2022
;
6
(
S3
):
1137
8
.
10.
Breccia
M
,
Abruzzese
E
,
Castagnetti
F
,
Bonifacio
M
,
Gangemi
D
,
Sorà
F
, et al
.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
.
Ann Hematol
.
2018
;
97
(
9
):
1577
80
.
11.
Latagliata
R
,
Attolico
I
,
Trawinska
MM
,
Capodanno
I
,
Annunziata
M
,
Elena
C
, et al
.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors
.
Hematol Oncol
.
2021
;
39
(
3
):
401
8
.
12.
Iurlo
A
,
Galimberti
S
,
Abruzzese
E
,
Annunziata
M
,
Bonifacio
M
,
Latagliata
R
, et al
.
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
.
Ann Hematol
.
2018
;
97
(
1
):
95
100
.
13.
Iurlo
A
,
Cattaneo
D
,
Consonni
D
,
Castagnetti
F
,
Miggiano
MC
,
Binotto
G
, et al
.
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: updated results from a campus CML real-life study
.
Front Pharmacol
.
2023
;
14
:
1154377
.
You do not currently have access to this content.